Table 2. Genotype/allele distributions of six examined polymorphisms between patients and controls and their risk prediction for CAD.
| Gene: polymorphism | CAD patients(n = 679) | Controls(n = 686) | Pχ2 | OR; 95% CI; P* | |
| ADH1B: rs1229984 | AA | 329 | 327 | 0.97; 0.83–1.14; 0.755 | |
| Genotype (n): | AG | 282 | 288 | 0.952 | 0.97; 0.78–1.20; 0.771 |
| GG | 68 | 71 | 0.96; 0.68–1.37; 0.838 | ||
| Allele (%): | G | 30.78 | 36.07 | 0.752 | |
| ADH1C: rs1693482 | CC | 650 | 666 | 1.54; 0.89–2.68; 0.126 | |
| Genotype (n): | CT | 27 | 20 | 0.202 | 1.49; 0.83–2.56; 0.181 |
| TT | 2 | 0 | NA | ||
| Allele (%): | T | 2.28 | 1.46 | 0.111 | |
| ALDH1b1: rs2228093 | CC | 256 | 236 | 0.93; 0.8–1.08; 0.338 | |
| Genotype (n): | CT | 302 | 325 | 0.430 | 0.87; 0.6901.08; 0.204 |
| TT | 121 | 125 | 0.97; 0.74–1.28; 0.847 | ||
| Allele (%): | T | 40.06 | 41.91 | 0.326 | |
| ALDH1b1: rs2073478 | GG | 239 | 299 | 1.29; 1.10–1.51; 0.001 | |
| Genotype (n): | GT | 338 | 307 | 0.005 | 1.42; 1.14–1.77; 0.002 |
| TT | 102 | 80 | 1.34; 0.98–1.83; 0.068 | ||
| Allele (%): | T | 39.91 | 34.04 | 0.001 | |
| ALDH2: rs886205 | CC | 472 | 488 | 1.03; 0.83–1.28; 0.778 | |
| Genotype (n): | CT | 199 | 184 | 0.293 | 1.08; 0.86–1.36; 0.512 |
| TT | 8 | 14 | 0.57; 0.24–1.37; 0.211 | ||
| Allele (%): | T | 15.83 | 15.45 | 0.785 | |
| ALDH2: rs671 | GG | 324 | 367 | 1.27; 1.08–1.48; 0.003 | |
| Genotype (n): | GA | 259 | 258 | 0.005 | 1.26; 1.02–1.56; 0.033 |
| AA | 96 | 61 | 1.69; 1.20–2.37; 0.003 | ||
| Allele (%): | A | 33.21 | 27.70 | 0.002 | |
Abbreviations: CAD, coronary artery disease; OR, odds ratio; 95% CI, 95% confidence interval. *The upper risk estimates were calculated under an additive mode (major homozygotes versus heterozygotes versus minor homozygotes), the middle under a dominant mode (major homozygotes versus heterozygotes plus minor homozygotes) and the lower under a recessive mode (major homozygotes plus heterozygotes versus minor homozygotes).